SW
ALNY icon

SlateStone Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

SlateStone Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,100
Closed -$209K – 228
2023
Q2 		$209K Hold
1,100
– – 0.04% 202
2023
Q1 		$220K Hold
1,100
– – 0.05% 196
2022
Q4 		$261K Hold
1,100
– – 0.06% 168
2022
Q3 		$220K Buy
+1,100
New +$210K 0.06% 177

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SlateStone Wealth's ALNY Position: Q3 2023 in Review

SlateStone Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 1,100 shares — an estimated $209K sold.

SlateStone Wealth first reported a position in ALNY in Q3 2022 and held it in 4 quarters. The position peaked at $261K in Q4 2022. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • SlateStone Wealth reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • SlateStone Wealth sold 1,100 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $209K.
  • SlateStone Wealth first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • SlateStone Wealth's Alnylam Pharmaceuticals position peaked at $261K in Q4 2022.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on SlateStone Wealth's 13F filing for Q3 2023, filed 12 Oct 2023.